23-Oct-2026 18:02:20
SUNPHARMAGeneral news
SUNPHARMA : TO PRESENT LONG-TERM UNLOXCYT DATA AT ESMO 2026
• Updated long-term efficacy and safety data from pivotal CK-301-101 trial across three advanced CSCC cohorts, 205 patients • Group 2 (laCSCC) objective response rate 53.1% with complete response rate of 34.4% • Group 1 (mCSCC) ORR 51.3%, CR 16.7%; Group 3 (mCSCC) ORR 44.4%, CR 20.6% • Estimated probability of remaining in response at two years ranged 69% to 82% across cohorts • Safety profile consistent: 2.9% grade 3 immune-related adverse events, no grade 4 events or irAEs leading to death • Presentation on October 24, 2026 at ESMO Congress in Madrid, Spain; UNLOXCYT received US FDA approval in 2024
Sun Pharmaceutical Industries Ltd
Open attachment